CSIMarket Company Name, Ticker, Customers, else..
Madrigal Pharmaceuticals Inc   (NASDAQ: MDGL)
Other Ticker:  
 


 

Madrigal Pharmaceuticals Inc

MDGL's Financial Statements and Analysis



Madrigal Pharmaceuticals Inc increased third quarter of 2025 net loss per share of $-5.08 compare to net loss per share of $-4.92 recorded in the same quarter a year ago a decrease compare to $-1.90 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ -5.08 $  287 Mill
$-0.16     $+225M     +362.03 %



Madrigal Pharmaceuticals Inc 's Revenue rose by 362.03 % in third quarter of 2025 (Sep 30 2025) year on year, to $287 million and advanced by 34.99 % sequentially.


Madrigal Pharmaceuticals Inc is

More on MDGL's Income Statement



Madrigal Pharmaceuticals Inc in the third quarter of 2025 recorded net loss of $-114.190 million, an increase from net loss of $-106.964 million in III. Quarter a year ago.

Sequentially net loss advanced

More on MDGL's Growth

Madrigal Pharmaceuticals Inc Inventories
Inventories grew by 695.38 % to $69 million from III. Quarter a year ago, sequentially inventories rose by 9.17 %. MDGL's Cash flow In the third quarter of 2025 company's net cash flow was $110 million, capital expenditures fell by -0.779395.12%, to $-4 millions compare to same quarter a year ago

More on MDGL's Cash flow Statement


Madrigal Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Madrigal Pharmaceuticals Inc payed $ -7.14 cash per share, on a free-cash flow basis .

Book value fell by -11.19 % sequentially to $27.83 per share, -27.72% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 27.50 per share from $ 31.14.

Company issued 0.28 million shares or 1.24 % in Sep 30 2025.


• More on MDGL's Dividends

 Market Capitalization (Millions) 11,898
 Shares Outstanding (Millions) 22
 Total Debt (Millions $) 340
 Revenue (TTM) (Millions $) 741
 Net Income (TTM) (Millions $) -289
 Cash Flow (TTM) (Millions $) 63
 Capital Exp. (TTM) (Millions $) -4
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 53




Madrigal Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Madrigal Pharmaceuticals Inc had negative $ -7.14 cash flow per share, on a free-cash flow basis .

Book value fell by -11.19 % sequentially to $27.83 per share, -27.72% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 27.50 per share from $ 31.14.

Company issued 0.28 million shares or 1.24 % in Sep 30 2025.


• More on MDGL's Balance Sheets

 Market Capitalization (Millions) 11,898
 Shares Outstanding (Millions) 22
 Total Debt (Millions $) 340
 Revenue (TTM) (Millions $) 741
 Net Income (TTM) (Millions $) -289
 Cash Flow (TTM) (Millions $) 63
 Capital Exp. (TTM) (Millions $) -4
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 53
   


  News about Madrigal Pharmaceuticals Inc Earnings

Madrigal Pharmaceuticals Inc. Achieves Impressive $62.175 Million Revenue in Q3 2024!

Madrigal Pharmaceuticals Inc: A Bullish Outlook Despite Recent Financial ChallengesIn the ever-evolving landscape of biopharmaceuticals, Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has emerged as a compelling narrative, resonating with investors seeking promising opportunities in a sector marked by volatility and innovation. The company's recent financial results for the fiscal period ending September 30, 2024, have sparked discussions regarding its potential, despite reporting a net loss. With $62.175 million in revenue, Madrigal's future prospects continue to appear bright against the backdrop of a dynamic market. Financial Performance: Understanding the NumbersMadrigal Pharmaceuticals reported $62.175 mi...

Madrigal Pharmaceuticals Inc. Surprises Investors with Upsized $600 Million Public Offering Despite Widening Operating Deficit

Investors in Madrigal Pharmace...

Madrigal Pharmaceuticals Inc Faces Decline in Shares, Operating Loss in Fourth Quarter of 2023

Madrigal Pharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing therapeutics for nonalcoholic steatohepatitis (NASH), has experienced a decline in its shares in February 2024. The shares dropped by 6.44% so far this month, and by 14.36% compared to the same period last year. Despite this, Madrigal Pharmaceuticals Inc shares are currently trading on the NASDAQ at 9.1% above its 52-week average.
In the recent months, shareholders did not anticipate any changes to the company's top-line revenue during the October to December 2023 reporting cycle. However, they closely monitored the operating loss of Madrigal Pharmaceuticals Inc, which amounted to $-117.176 million during the s...

Madrigal Pharmaceuticals Inc. Struggles to Contain Soaring Business Expenses during the Period of July to September 30, 2023


Date: November 6, 2023

Following the recent financial results of major players in the Major Pharmaceutical Preparations sector, smaller entities like Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) have now reported their numbers. Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in therapeutics for nonalcoholic steatohepatitis (NASH), has announced a third-quarter operating shortfall of $-98.534 million, representing a decline from the previous year. While the company's net deficit has also increased in the same time frame, analysts are optimistic about its future performance.
Operating Shortfall and Increased Deficit
Madrigal Pharmaceuticals has reported a t...

Madrigal Pharmaceuticals Inc Faces Deteriorating Business Results with $-86.45 Million Operating Loss in Q2 2023

Madrigal Pharmaceuticals Inc, a smaller corporation in the Major Pharmaceutical Preparations sector, recently reported an operating loss of $-86.45 million for the second quarter of 2023. While the company has not yet announced its top-line figures, it is evident that the company's performance has been consistently poor over the past few quarters.
Looking back at the second quarter of 2022, Madrigal Pharmaceuticals Inc recorded an operating loss of $-70.273 million. This suggests that the company's financial difficulties have persisted and potentially worsened over time. Additionally, the net loss for the emerging period has increased from $-70.730 million to $-85.800 million compared to the same period ...

Madrigal Pharmaceuticals Inc Faces Operating Deficit and Revenue Speculation Amidst Turbulent Times

Madrigal Pharmaceuticals Inc: Navigating Uncertainty in the Biotech Industry
Madrigal Pharmaceuticals Inc is a biopharmaceutical company that is dedicated to developing novel drugs for cardiovascular, metabolic, and liver-related diseases. As a major player in the pharmaceutical preparations industry, Madrigal has been experiencing some turbulence in recent months. The company has been struggling with an operating deficit, which has only worsened in the past few quarters. Additionally, market participants are anxiously awaiting the announcement of any revenue-generating news from the company.
Madrigal's latest financial results have shown an operating deficit of -$78.336 million in the first quarter ...


Date modified: 2025-11-04T21:24:30+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.